<DOC>
	<DOCNO>NCT01919216</DOCNO>
	<brief_summary>The placebo effect represent potent treatment MDD—placebo response acute randomize control trial ( RCTs ) antidepressant medication average 30 % , meta-analyses estimate proportion medication response attributable placebo 50-75 % . Patient expectancy mechanism placebo effect antidepressant RCTs positively associate medication response . Determining expectancy alters course MDD could lead method optimize placebo effect improve treatment MDD . In addition , investigate neurobiology placebo effect potential elucidate pathophysiology MDD mechanisms action antidepressant treatment . Brain region implicate expectancy placebo effect comprise prefrontal cortical ( PFC ) area , amygdala , insular cortex , rostral anterior cingulate cortex ( rACC ) , dopaminergic reward pathways striatum . Pathological decrease PFC striatal function , increase limbic activity , disorder connectivity region observe MDD , rostral dorsal ACC repeatedly link antidepressant treatment response . Therefore , study placebo effect offer window function neural circuit disturb MDD improve effective treatment . The goal study determine whether expectancy affect outcome antidepressant pharmacotherapy investigate neural mechanism expectancy effect . These accomplish conduct clinical trial randomize adult outpatient MDD 8 week treatment high vs. low expectancy condition . The high expectancy condition open administration citalopram , low expectancy condition placebo-controlled administration citalopram . The neural mechanism expectancy determine use functional Magnetic Resonance Imaging ( fMRI ) paradigm investigate treatment activation difference brain region associate placebo effect MDD .</brief_summary>
	<brief_title>Placebo Effects Treatment Depression : Cognitive Neural Mechanisms</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Men woman age 2475 year Diagnosed DSM IV Major Depressive Disorder , nonpsychotic 24item Hamilton Rating Scale Depression ( HRSD ) score ≥ 16 Willing capable providing inform consent comply study procedure Subjects righthanded Using appropriate contraceptive method woman childbearing age Current comorbid Axis I DSM IV disorder Nicotine Dependence , Adjustment Disorder , Panic Disorder , Generalized Anxiety Disorder , Social Phobia Diagnosis substance abuse dependence ( exclude Nicotine Dependence ) within past 12 month History psychosis psychotic disorder , mania bipolar disorder Subject consider significant risk suicide base current mental status recent history History allergic adverse reaction citalopram , nonresponse adequate trial citalopram ( least 4 week dose 40mg ) escitalopram ( least 4 week dose 20mg ) Subject consider base history unlikely respond single agent citalopram ( i.e. , subject treatment resistant depression ) Current treatment psychotherapy CGISeverity score 7 baseline Clinical Interview Current recent ( within past 4 week ) treatment follow : antidepressant , antipsychotic , mood stabilizer , isoniazid , glucocorticoid , opiate , centrally active antihypertensive drug ( e.g . clonidine , reserpine ) Subject metal body prior history work metal fragment ( e.g. , machinist ) , tattoos , unable tolerate scanning procedure ( i.e. , severe obesity , claustrophobia ) Acute , severe , unstable medical illness</criteria>
	<gender>Female</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>